Top

Published in:

01-02-2016 | Laboratory Investigation

Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells

Authors: Richard E. Kast, Susana Ramiro, Sandra Lladó, Salvador Toro, Rafael Coveñas, Miguel Muñoz

Published in: Journal of Neuro-Oncology | Issue 3/2016

Abstract

In the effort to find better treatments for glioblastoma we tested several currently marketed non-chemotherapy drugs for their ability to enhance the standard cytotoxic drug currently used to treat glioblastoma- temozolomide. We tested four antiviral drugs- acyclovir, cidofovir, maraviroc, ritonavir, and an anti-emetic, aprepitant. We found no cytotoxicity of cidofovir and discussed possible reasons for discrepancy from previous findings of others. We also found no cytotoxicity from acyclovir or maraviroc also in contradistinction to predictions. Cytotoxicity to glioma cell line GAMG for temozolomide alone was 14 %, aprepitant alone 7 %, ritonavir alone 14 %, while temozolomide + aprepitant was 19 %, temozolomide + ritonavir 34 %, ritonavir + aprepitant 64 %, and all three, temozolomide + ritonavir + aprepitant 78 %. We conclude that a remarkable synergy exists between aprepitant and ritonavir. Given the long clinical experience with these two well-tolerated drugs in treating non-cancer conditions, and the current median survival of glioblastoma of 2 years, a trial is warranted of adding these two simple drugs to current standard treatment with temozolomide.

Frosina G (2015) Limited advances in therapy of glioblastoma trigger re-consideration of research policy. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2015.05.013 PubMed

Alifieris C, Trafalis DT (2015) Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther 152:63–82PubMedCrossRef

Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20(4):450–458PubMedCrossRef

Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 39(1):113–117PubMedCrossRef

Coveñas R, Muñoz M (2014) Cancer progression and substance P. Histol Histopathol 29(7):881–890PubMed

Kast RE (2009) Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. Clin Transl Oncol 11(7):408–410PubMedCrossRef

Kast RE, Karpel-Massler G, Halatsch ME (2014) CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 5(18):8052–8082PubMedPubMedCentralCrossRef

Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Dueñas-González A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, Marosi C, McDonald K, Muñoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME (2013) A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4(4):502–530PubMedPubMedCentralCrossRef

Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S (2000) Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 82(2):480–487PubMedPubMedCentralCrossRef

10.

Muñoz M, Rosso M (2010) The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs 28(2):187–193PubMedCrossRef

11.

De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16(4):569–596PubMedPubMedCentralCrossRef

12.

Van Pachterbeke C, Bucella D, Rozenberg S, Manigart Y, Gilles C, Larsimont D, Vanden Houte K, Reynders M, Snoeck R, Bossens M (2009) Topical treatment of CIN 2 + by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol 115(1):69–74PubMedCrossRef

13.

Moyo TK, Richards KL, Damania B (2010) Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma. Clin Adv Hematol Oncol 8(5):372–374PubMedPubMedCentral

14.

De Schutter T, Andrei G, Topalis D, Naesens L, Snoeck R (2013) Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med Genomics 6:18PubMedPubMedCentralCrossRef

15.

Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS (2013) Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res 19(23):6473–6483PubMedPubMedCentralCrossRef

16.

Liekens S, Noppen S, Gijsbers S, Sienaert R, Ronca R, Tobia C, Presta M (2015) The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. Oncotarget 6(7):4633–4648PubMedPubMedCentralCrossRef

17.

Wang F, Yang L, Shi L, Li Q, Zhang G, Wu J, Zheng J, Jiao B (2015) Nuclear translocation of fibroblast growth factor-2 (FGF2) is regulated by karyopherin-Î²2 and Ran GTPase in human glioblastoma cells. Oncotarget 6(25):21468–21478PubMedPubMedCentralCrossRef

18.

Wu J, Feng X, Zhang B, Li J, Xu X, Liu J, Wang X, Wang J, Tong X (2014) Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells. J Neurooncol 120(1):33–41PubMedCrossRef

19.

Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C (2014) Preclinical evidence that SSR128129E- a novel small-molecule multi-fibroblast growth factor receptor blocker- radiosensitises human glioblastoma. Eur J Cancer 50(13):2351–2359PubMedCrossRef

20.

Haley EM, Kim Y (2014) The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture. Cancer Lett 346(1):1–5PubMedCrossRef

21.

Lieberman-Blum SS, Fung HB, Bandres JC (2008) Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 30(7):1228–1250PubMedCrossRef

22.

Kast RE (2010) Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther 35(6):657–663PubMedCrossRef

23.

Rappa F, Cappello F, Halatsch ME, Scheuerle A, Kast RE (2013) Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells. Biochimie 95(4):782–786PubMedCrossRef

24.

Kast RE (2015) The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir. Chin J Cancer 34(4):161–165PubMed

25.

Sato A (2015) The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies. Onco Targets Ther 8:761–768PubMedPubMedCentralCrossRef

26.

Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10(1):61–71PubMedCrossRef

27.

Liu R, Zhang L, Yang J, Zhang X, Mikkelsen R, Song S, Zhou H (2015) HIV protease inhibitors sensitize human head and neck squamous carcinoma cells to radiation by activating endoplasmic reticulum stress. PLoS One 10(5):e0125928PubMedPubMedCentralCrossRef

28.

Laurent N, de Bouard S, Guillamo JS, Christov C, Zini R, Jouault H, Andre P, Lotteau V, Peschanski M (2004) Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3(2):129–136PubMed

29.

Bruening A, Jueckstock J (2015) Misfolded proteins: from little villains to little helpers in the fight against cancer. Front Oncol 5:47

30.

Weiss M, Kost B, Renner-Mueller I, Wolf E, Mylonas I, Bruening A (2015) Efavirenz causes oxidative stress, endoplasmic reticulum stress, and autophagy in endothelial cells. Cardiovasc Toxicol. doi:10.1007/s12012-015-9314-2

31.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 13(17):5183–5194PubMedCrossRef

32.

Muñoz M, Coveñas R (2013) Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 48:1–9PubMedCrossRef

33.

Muñoz M, Rosso M, Pérez A, Coveñas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39(4):427–432PubMedCrossRef

34.

Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S (1992) Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected Chinese hamster ovary cells. J Biol Chem 267(4):2437–2442PubMed

35.

Takeda Y, Blount P, Sachais BS, Hershey AD, Raddatz R, Krause JE (1992) Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and cyclic AMP second messenger responses. J Neurochem 59(2):740–745PubMedCrossRef

36.

Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109(4):1079–1086PubMedPubMedCentralCrossRef

37.

Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen ST, Shanmugam M (2015) Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res 21(5):1161–1171PubMedCrossRef

38.

Batchu RB, Gruzdyn OV, Bryant CS, Qazi AM, Kumar S, Chamala S, Kung ST, Sanka RS, Puttagunta US, Weaver DW, Gruber SA (2014) Ritonavir-mediated induction of apoptosis in pancreatic cancer occurs via the RB/E2F-1 and AKT pathways. Pharmaceuticals (Basel) 7(1):46–57CrossRef

39.

Kraus M, Mueller-Ide H, Rueckrich T, Bader J, Overkleeft H, Driessen C (2014) Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. Leuk Res 38(3):383–392PubMedCrossRef

40.

Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD (2010) Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 24(18):2789–2796PubMedPubMedCentralCrossRef

41.

Muñoz M, Coveñas R (2013) Safety of neurokinin-1 receptor antagonists. Expert Opin Drug Saf 12(5):673–685PubMedCrossRef

42.

Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, Wyatt-knowles E, Halle JJ, Mills SG, MacCoss M, Swain CJ, Harrison T, Hill RG, Hefti F, Scolnick EM, Cascieri MA, Chicchi GG, Sadowski S, Williams AR, Hewson L, Smith D, Carlsson EJ, Hargreaves RJ, Rupniak NM (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383):1640–1645PubMedCrossRef

43.

Harford-Wright E, Lewis KM, Ghabriel MN, Vink R (2014) Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors. PLoS ONE 9(5):e97002PubMedPubMedCentralCrossRef

44.

Endo T, Saijo T, Haneda E, Maeda J, Tokunaga M, Zhang MR, Kannami A, Asai H, Suzuki M, Suhara T, Higuchi M (2015) Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography. Int J Neuropsychopharmacol 18(2):pyu030PubMedCentralCrossRef

45.

Bergström M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Långström B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J (2004) Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 55(10):1007–1012PubMedCrossRef

46.

Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA (2004) The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol ExpTher 308(3):912–920CrossRef

Title: Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells
Authors: Richard E. Kast
Susana Ramiro
Sandra Lladó
Salvador Toro
Rafael Coveñas
Miguel Muñoz
Publication date: 01-02-2016
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2016
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1996-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

ATP5A1 and ATP5B are highly expressed in glioblastoma tumor cells and endothelial cells of microvascular proliferation

Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients

TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas

Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma

Usefulness of 11C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions

Pseudoprogression in glioblastoma patients: the impact of extent of resection